Cachexia - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Cachexia - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cachexia: Overview
Cachexia is a “wasting” disorder that causes extreme weight loss and muscle wasting, and can include loss of body fat. It is a symptom of many chronic conditions, such as cancer, chronic renal failure, HIV, and multiple sclerosis. The main symptoms of the conditions are severe weight loss, including loss of fat and muscle mass, loss of appetite, anemia (low red blood cells), weakness and fatigue. Cachexia adversely affects the patients’ ability to fight against infection and withstand treatment by chemotherapy and radiotherapy. The goal of treatment for cachexia is to improve symptoms and quality of life. Current therapy for cachexia includes: appetite stimulants such as megestrol acetate drugs, medications that decrease inflammation, diet changes, nutritional supplements and exercise.
'Cachexia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cachexia pipeline landscape is provided which includes the disease overview and Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cachexia Emerging Drugs
Further product details are provided in the report..
Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
Cachexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.
Cachexia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cachexia - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cachexia: Overview
Cachexia is a “wasting” disorder that causes extreme weight loss and muscle wasting, and can include loss of body fat. It is a symptom of many chronic conditions, such as cancer, chronic renal failure, HIV, and multiple sclerosis. The main symptoms of the conditions are severe weight loss, including loss of fat and muscle mass, loss of appetite, anemia (low red blood cells), weakness and fatigue. Cachexia adversely affects the patients’ ability to fight against infection and withstand treatment by chemotherapy and radiotherapy. The goal of treatment for cachexia is to improve symptoms and quality of life. Current therapy for cachexia includes: appetite stimulants such as megestrol acetate drugs, medications that decrease inflammation, diet changes, nutritional supplements and exercise.
'Cachexia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cachexia pipeline landscape is provided which includes the disease overview and Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cachexia.
This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cachexia Emerging Drugs
- GCWB 204: Green Cross Wellbeing
- Ponsegromab: Pfizer
Further product details are provided in the report..
Cachexia: Therapeutic Assessment
This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cachexia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cachexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.
Cachexia Report Insights
- Cachexia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cachexia drugs?
- How many Cachexia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cachexia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cachexia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cachexia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Incyte Corporation
- Green Cross Wellbeing
- AEterna Zentaris
- AVEO Oncology
- AstraZeneca
- Endevica Bio
- Actimed Therapeutics
- Creative Medical Technology Holdings
- Ildong Pharmaceutical
- Immuneering
- Ruxolitinib
- GCWB 204
- Macimorelin
- AV 380
- ART 2713
- TCMCB-07
- ACM-002
- Research programme: amniotic stem cell therapies
- ID 11917
- Research programme: cancer therapeutics
Introduction
Executive Summary
Cachexia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cachexia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cachexia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cachexia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
GCWB 204: Green Cross Wellbeing
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Ponsegromab: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
TCMCB-07: Endevica Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Cachexia Key Companies
Cachexia Key Products
Cachexia- Unmet Needs
Cachexia- Market Drivers and Barriers
Cachexia- Future Perspectives and Conclusion
Cachexia Analyst Views
Cachexia Key Companies
Appendix
Executive Summary
Cachexia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cachexia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cachexia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cachexia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
GCWB 204: Green Cross Wellbeing
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Ponsegromab: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
TCMCB-07: Endevica Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Cachexia Key Companies
Cachexia Key Products
Cachexia- Unmet Needs
Cachexia- Market Drivers and Barriers
Cachexia- Future Perspectives and Conclusion
Cachexia Analyst Views
Cachexia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cachexia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cachexia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cachexia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cachexia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
